← Back to Clinical Trials
Recruiting NCT06757257
NCT06757257 Special Drug Use-results Survey for Long-term Use (Fostamatinib)
◆ AI Clinical Summary
Plain-language summary for patients
| NCT ID | NCT06757257 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Kissei Pharmaceutical Co., Ltd. |
| Condition | Chronic Idiopathic Thrombocytopenic Purpura |
| Study Type | OBSERVATIONAL |
| Enrollment | 149 participants |
| Start Date | 2023-05-29 |
| Primary Completion | 2028-09-30 |
Trial Parameters
Condition Chronic Idiopathic Thrombocytopenic Purpura
Sponsor Kissei Pharmaceutical Co., Ltd.
Study Type OBSERVATIONAL
Phase N/A
Enrollment 149
Sex ALL
Min Age N/A
Max Age N/A
Start Date 2023-05-29
Completion 2028-09-30
Interventions
fostamatinib
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The purpose of this survey is evaluating the safety and efficacy of long-term administration of fostamatinib for Japanese patients with chronic idiopathic thrombocytopenic purpura under actual conditions of use.
Eligibility Criteria
Inclusion Criteria: * Patients with chronic idiopathic thrombocytopenic purpura who are treatment with fostamatinib for the first time.
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology